董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vlad Coric | 男 | Independent Director | 55 | 0.79万美元 | 65.37 | 2026-03-25 |
| Patrick Enright | 男 | Independent Director | 64 | 未披露 | 465.39 | 2026-03-25 |
| Reid Waldman | 男 | Chief Executive Officer and Director | 31 | 845.55万美元 | 81.82 | 2026-03-25 |
| David Friedman | 男 | Independent Director | 51 | 未披露 | 未持股 | 2026-03-25 |
| Jane Grant Kels | 女 | Independent Director | 76 | 未披露 | 2.24 | 2026-03-25 |
| Katarina Pance | 女 | Independent Director | 29 | 未披露 | 未持股 | 2026-03-25 |
| John W. Childs | 男 | Independent Director | 84 | 未披露 | 220.20 | 2026-03-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael V. Greco | 男 | General Counsel | 55 | 未披露 | 未持股 | 2026-03-25 |
| Reid Waldman | 男 | Chief Executive Officer and Director | 31 | 845.55万美元 | 81.82 | 2026-03-25 |
| Dominic Carrano | 男 | Chief Financial Officer and Treasurer | 40 | 221.15万美元 | 10.39 | 2026-03-25 |
| Tim Durso | 男 | Chief Technical Officer | 36 | 330.85万美元 | 54.90 | 2026-03-25 |
| Mark Neumann | 男 | Chief Commercial and Strategy Officer | 62 | 未披露 | 未持股 | 2026-03-25 |
董事简历
中英对照 | 中文 | 英文- Vlad Coric
-
Vlad Coric自2015年10月以来一直担任我们的首席执行官兼董事。从2007年1月到2015年9月，他曾担任百时美施贵宝公司全球临床研究的集团董事，专注于肿瘤全球临床研究和神经科学全球临床研究。他曾参与多种药物开发计划，包括上市药物，如Abilify Aripiprazo、部分多巴胺激动剂、Opdivo（nivolumab；抗PD1）、Yervoy（ipilimumab；抗CTLA-4）、Daklinza（达克拉他韦；NS5a抑制剂）和Sunvepra（阿舒那普利；NS3抑制剂）。自2001年7月以来，Coric博士还继续担任耶鲁医学院精神病学的临床副教授。他此前曾担任the Yale Clinical Neuroscience Research Unit的负责人，以及the Yale Obsessive-Prediction Disorder Research Clinic的董事。他曾担任the Connecticut Psychiatric Society的总裁。Coric博士在维克森林大学医学院（Wake Forest University School of Medicine）获得医学博士学位。他在耶鲁大学纽黑文医院（Yale-New Haven Hospital）完成实习，并在耶鲁大学精神病学住院医师培训计划（Yale Psychiatry Residency Training Program）完成住院医师培训，在那里他还担任耶鲁大学精神病学系的全项目首席住院医师，以及西黑文康涅狄格州退伍军人管理局医院PTSD公司的首席住院医师。Coric博士是康涅狄格大学（University of Connecticut）的神经生物学和生理学荣誉学者，在那里他获得了B.S.学位。
Vlad Coric has served as a member of VeraDermics, Incorporated board of directors since September 2021. Dr. Coric has served as Chief Executive Officer of Biohaven since October 2022. Dr. Coric has also served as a Clinical Professor at Yale School of Medicine since July 2021. From October 2015 to October 2022, Dr. Coric served as Chief Executive Officer of Biohaven Pharmaceutical Holding Company Limited, until it was sold to Pfizer Inc. Prior to that, Dr. Coric served a Group Director, Global Clinical Research at Bristol Myers Squibb Company. Dr. Coric is currently a member of the board of directors of Biohaven and Royalty Pharma plc. Dr. Coric also served on the board of directors of Revance Therapeutics, Inc. from March 2023 to February 2025, Biohaven Pharmaceutical Holding Company Ltd., from October 2015 to October 2022, and Social Capital Suvretta Holdings Corp. I, from June 2021 through July 2022. Dr. Coric received his B.S. in Neurobiology and Physiology from the University of Connecticut and his M.D. from Wake Forest University School of Medicine. He completed his internship at Yale New Haven Hospital and residency training at the Yale Psychiatry Residency Training Program. - Vlad Coric自2015年10月以来一直担任我们的首席执行官兼董事。从2007年1月到2015年9月，他曾担任百时美施贵宝公司全球临床研究的集团董事，专注于肿瘤全球临床研究和神经科学全球临床研究。他曾参与多种药物开发计划，包括上市药物，如Abilify Aripiprazo、部分多巴胺激动剂、Opdivo（nivolumab；抗PD1）、Yervoy（ipilimumab；抗CTLA-4）、Daklinza（达克拉他韦；NS5a抑制剂）和Sunvepra（阿舒那普利；NS3抑制剂）。自2001年7月以来，Coric博士还继续担任耶鲁医学院精神病学的临床副教授。他此前曾担任the Yale Clinical Neuroscience Research Unit的负责人，以及the Yale Obsessive-Prediction Disorder Research Clinic的董事。他曾担任the Connecticut Psychiatric Society的总裁。Coric博士在维克森林大学医学院（Wake Forest University School of Medicine）获得医学博士学位。他在耶鲁大学纽黑文医院（Yale-New Haven Hospital）完成实习，并在耶鲁大学精神病学住院医师培训计划（Yale Psychiatry Residency Training Program）完成住院医师培训，在那里他还担任耶鲁大学精神病学系的全项目首席住院医师，以及西黑文康涅狄格州退伍军人管理局医院PTSD公司的首席住院医师。Coric博士是康涅狄格大学（University of Connecticut）的神经生物学和生理学荣誉学者，在那里他获得了B.S.学位。
- Vlad Coric has served as a member of VeraDermics, Incorporated board of directors since September 2021. Dr. Coric has served as Chief Executive Officer of Biohaven since October 2022. Dr. Coric has also served as a Clinical Professor at Yale School of Medicine since July 2021. From October 2015 to October 2022, Dr. Coric served as Chief Executive Officer of Biohaven Pharmaceutical Holding Company Limited, until it was sold to Pfizer Inc. Prior to that, Dr. Coric served a Group Director, Global Clinical Research at Bristol Myers Squibb Company. Dr. Coric is currently a member of the board of directors of Biohaven and Royalty Pharma plc. Dr. Coric also served on the board of directors of Revance Therapeutics, Inc. from March 2023 to February 2025, Biohaven Pharmaceutical Holding Company Ltd., from October 2015 to October 2022, and Social Capital Suvretta Holdings Corp. I, from June 2021 through July 2022. Dr. Coric received his B.S. in Neurobiology and Physiology from the University of Connecticut and his M.D. from Wake Forest University School of Medicine. He completed his internship at Yale New Haven Hospital and residency training at the Yale Psychiatry Residency Training Program.
- Patrick Enright
-
Patrick Enright自2015年7月以来一直担任我们的董事会成员。Enright自2006年1月起担任Longitude Capital Management（一家梦百合风险投资公司）总经理。恩赖特先生目前担任临床阶段生物制药公司Aimmune治疗公司、临床阶段制药公司AptinyxInc.和制药公司Jazz Pharmaceuticals plc的董事会成员，以及私营生命科学公司的董事会成员。Enright先生拥有斯坦福大学（Stanford University）生物科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
Patrick Enright has served as a member of VeraDermics, Incorporated board of directors since December 2024. Mr. Enright has served as a Managing Director of Longitude Capital Management Co., LLC, a healthcare venture capital firm co founded by Mr. Enright, since 2006. Previously, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co led the life sciences investment practice, and served in various senior executive positions at Valentis Inc., Boehringer Mannheim Pharmaceuticals Corp. and Sandoz Inc. Mr. Enright is currently a member of the board of directors of BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc. and Zenas BioPharma, Inc., and has served on such boards since February 2024, January 2012, October 2020 and November 2022, respectively. Mr. Enright also served on the board of directors of Aptinyx Inc. from March 2016 to December 2022. Mr. Enright received his B.S. in Biological Sciences from Stanford University and his M.B.A. from the Wharton School of the University of Pennsylvania. - Patrick Enright自2015年7月以来一直担任我们的董事会成员。Enright自2006年1月起担任Longitude Capital Management（一家梦百合风险投资公司）总经理。恩赖特先生目前担任临床阶段生物制药公司Aimmune治疗公司、临床阶段制药公司AptinyxInc.和制药公司Jazz Pharmaceuticals plc的董事会成员，以及私营生命科学公司的董事会成员。Enright先生拥有斯坦福大学（Stanford University）生物科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
- Patrick Enright has served as a member of VeraDermics, Incorporated board of directors since December 2024. Mr. Enright has served as a Managing Director of Longitude Capital Management Co., LLC, a healthcare venture capital firm co founded by Mr. Enright, since 2006. Previously, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co led the life sciences investment practice, and served in various senior executive positions at Valentis Inc., Boehringer Mannheim Pharmaceuticals Corp. and Sandoz Inc. Mr. Enright is currently a member of the board of directors of BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc. and Zenas BioPharma, Inc., and has served on such boards since February 2024, January 2012, October 2020 and November 2022, respectively. Mr. Enright also served on the board of directors of Aptinyx Inc. from March 2016 to December 2022. Mr. Enright received his B.S. in Biological Sciences from Stanford University and his M.B.A. from the Wharton School of the University of Pennsylvania.
- Reid Waldman
-
雷德·沃尔德曼是联合创始人，自2022年12月起担任首席执行官。在担任首席执行官之前，Waldman博士曾于2020年3月至2022年12月担任首席运营官。Waldman博士自2019年10月起担任董事会成员。从2019年3月至2021年6月，Waldman博士担任康涅狄格大学健康中心的临床试验住院医师，并于2018年6月至2021年6月担任皮肤科住院医师。在住院之前，Waldman医生完成了在Cedars Sinai医疗中心的实习。Waldman博士是一名获得董事会认证的皮肤科医生，并获得了米西堪萨斯城大学6年B. A./M.D.项目的学士和医学博士学位。
Reid Waldman has served as Chief Executive Officer of Veradermics, Incorporated since 2019. Dr. Waldman is a board certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a researcher authoring more than 100 publications. He earned his B.A. and his M.D. degrees from the University of Missouri Kansas City 6 Year B.A./M.D. Program and completed his dermatology residency with a "Distinction in Clinical Trials" at the University of Connecticut. - 雷德·沃尔德曼是联合创始人，自2022年12月起担任首席执行官。在担任首席执行官之前，Waldman博士曾于2020年3月至2022年12月担任首席运营官。Waldman博士自2019年10月起担任董事会成员。从2019年3月至2021年6月，Waldman博士担任康涅狄格大学健康中心的临床试验住院医师，并于2018年6月至2021年6月担任皮肤科住院医师。在住院之前，Waldman医生完成了在Cedars Sinai医疗中心的实习。Waldman博士是一名获得董事会认证的皮肤科医生，并获得了米西堪萨斯城大学6年B. A./M.D.项目的学士和医学博士学位。
- Reid Waldman has served as Chief Executive Officer of Veradermics, Incorporated since 2019. Dr. Waldman is a board certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a researcher authoring more than 100 publications. He earned his B.A. and his M.D. degrees from the University of Missouri Kansas City 6 Year B.A./M.D. Program and completed his dermatology residency with a "Distinction in Clinical Trials" at the University of Connecticut.
- David Friedman
-
David Friedman自2025年12月起担任董事会成员。自2020年1月起，弗里德曼博士担任Suvretta Capital Management，LLC或Suvretta Capital的董事总经理和高级分析师。在加入Suvretta Capital之前，Friedman博士曾担任Scopia Capital Management LP的医疗保健分析师，并曾在摩根士丹利 & Co. LLC从事生物技术股票研究工作。弗里德曼博士在杜克大学获得生物学学士学位，在匹兹堡大学医学院获得医学博士学位，在哈佛大学比尼斯学院获得工商管理硕士学位。
David Friedman has been a member of Avalyn Pharma Inc.'s board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology. - David Friedman自2025年12月起担任董事会成员。自2020年1月起，弗里德曼博士担任Suvretta Capital Management，LLC或Suvretta Capital的董事总经理和高级分析师。在加入Suvretta Capital之前，Friedman博士曾担任Scopia Capital Management LP的医疗保健分析师，并曾在摩根士丹利 & Co. LLC从事生物技术股票研究工作。弗里德曼博士在杜克大学获得生物学学士学位，在匹兹堡大学医学院获得医学博士学位，在哈佛大学比尼斯学院获得工商管理硕士学位。
- David Friedman has been a member of Avalyn Pharma Inc.'s board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology.
- Jane Grant Kels
-
Jane Grant Kels自2021年9月起担任董事会成员。Grant Kels博士目前担任皮肤科副主任、Cutaneo肿瘤中心和黑色素瘤项目的创始主任以及康涅狄格大学健康中心皮肤科、病理学和儿科教授，自1979年以来，她在那里担任过多个职位，包括UCONN Health皮肤科的创始主席。Grant Kels博士于1971年获得史密斯学院的学士学位，并于1974年获得康奈尔大学医学院的医学博士学位。她完成了在纽约医院——康奈尔医学中心的实习和在纽约医院——康奈尔医学中心住院医师项目的住院医师培训。
Jane Grant Kels has served as a member of VeraDermics, Incorporated board of directors since September 2021. Dr. Grant Kels currently serves the Vice Chair of the Department of Dermatology, the Founding Director of the Cutaneous Oncology Center and Melanoma Programs and Professor of Dermatology, Pathology and Pediatrics at the University of Connecticut Health Center, where she has held numerous positions since 1979 including Founding Chair of the Dermatology Department at UCONN Health. Dr. Grant Kels received her B.A. in 1971 from Smith College and her M.D. from Cornell University Medical College in 1974. She completed her internship at the New York Hospital — Cornell Medical Center and residency training at the New York Hospital — Cornell Medical Center Residency Program. - Jane Grant Kels自2021年9月起担任董事会成员。Grant Kels博士目前担任皮肤科副主任、Cutaneo肿瘤中心和黑色素瘤项目的创始主任以及康涅狄格大学健康中心皮肤科、病理学和儿科教授，自1979年以来，她在那里担任过多个职位，包括UCONN Health皮肤科的创始主席。Grant Kels博士于1971年获得史密斯学院的学士学位，并于1974年获得康奈尔大学医学院的医学博士学位。她完成了在纽约医院——康奈尔医学中心的实习和在纽约医院——康奈尔医学中心住院医师项目的住院医师培训。
- Jane Grant Kels has served as a member of VeraDermics, Incorporated board of directors since September 2021. Dr. Grant Kels currently serves the Vice Chair of the Department of Dermatology, the Founding Director of the Cutaneous Oncology Center and Melanoma Programs and Professor of Dermatology, Pathology and Pediatrics at the University of Connecticut Health Center, where she has held numerous positions since 1979 including Founding Chair of the Dermatology Department at UCONN Health. Dr. Grant Kels received her B.A. in 1971 from Smith College and her M.D. from Cornell University Medical College in 1974. She completed her internship at the New York Hospital — Cornell Medical Center and residency training at the New York Hospital — Cornell Medical Center Residency Program.
- Katarina Pance
-
Katarina Pance自2025年10月起担任董事会成员。Pance博士自2023年5月起担任SROne Capital Management的高级助理。从2022年2月到2023年5月，潘斯博士在EpiBiologics，Inc.担任高级科学家、发现生物学负责人，该公司是她于2021年7月共同创立的。Pance博士还曾于2021年7月至2022年1月在MPM Capital担任风险研究员。潘斯博士在宾夕法尼亚大学获得生物化学学士学位，在加州大学旧金山分校获得博士学位。
Katarina Pance has served as a member of VeraDermics, Incorporated board of directors since October 2025. Dr. Pance has served as a Senior Associate at SR One Capital Management since May 2023. From February 2022 to May 2023, Dr. Pance served as Senior Scientist, Head of Discovery Biology at EpiBiologics, Inc., which she co founded in July 2021. Dr. Pance also worked as a Venture Fellow at MPM Capital from July 2021 to January 2022. Dr. Pance received her B.A. in Biochemistry from the University of Pennsylvania and her Ph.D. from the University of California, San Francisco. - Katarina Pance自2025年10月起担任董事会成员。Pance博士自2023年5月起担任SROne Capital Management的高级助理。从2022年2月到2023年5月，潘斯博士在EpiBiologics，Inc.担任高级科学家、发现生物学负责人，该公司是她于2021年7月共同创立的。Pance博士还曾于2021年7月至2022年1月在MPM Capital担任风险研究员。潘斯博士在宾夕法尼亚大学获得生物化学学士学位，在加州大学旧金山分校获得博士学位。
- Katarina Pance has served as a member of VeraDermics, Incorporated board of directors since October 2025. Dr. Pance has served as a Senior Associate at SR One Capital Management since May 2023. From February 2022 to May 2023, Dr. Pance served as Senior Scientist, Head of Discovery Biology at EpiBiologics, Inc., which she co founded in July 2021. Dr. Pance also worked as a Venture Fellow at MPM Capital from July 2021 to January 2022. Dr. Pance received her B.A. in Biochemistry from the University of Pennsylvania and her Ph.D. from the University of California, San Francisco.
- John W. Childs
-
John W. Childs，2007年8月加入本公司担任董事。1995年起，他担任J.W. Childs Associates, L.P.的董事长、首席执行官，该公司目前持有本公司48%的普通流通股。1991-1995，他担任Thomas H. Lee Partners的高级总经理；1987-1990，担任其总经理。1987年之前，他在Prudential Insurance Company of America工作了17年，在投资领域担任过多个行政职务，最后的职务是高级总经理，负责资本市场部门，当时他管理着该公司大约770亿美元的固定收入投资组合，也包括资本市场部所有的杠杆收购方面的投资。他目前担任Sunny Delight Beverages Co.、Esselte Ltd.、Simcom, Inc.的董事；曾经担任Advantage Sales and Marketing, Inc. 和 CHG Healthcare Services, Inc.的董事。
John W. Childs has served as a member of VeraDermics, Incorporated board of directors since September 2021. Since 1995, Mr. Childs has served as Chairman of J.W. Childs Associates, L.P. Previously, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company and held various executive positions in the investment area at the Prudential Insurance Company of America, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. Mr. Childs is currently a member of the board of directors of Biohaven Ltd., or Biohaven. Mr. Childs received his B.A. in History and French from Yale University and his M.B.A. from Columbia Business School at Columbia University. - John W. Childs，2007年8月加入本公司担任董事。1995年起，他担任J.W. Childs Associates, L.P.的董事长、首席执行官，该公司目前持有本公司48%的普通流通股。1991-1995，他担任Thomas H. Lee Partners的高级总经理；1987-1990，担任其总经理。1987年之前，他在Prudential Insurance Company of America工作了17年，在投资领域担任过多个行政职务，最后的职务是高级总经理，负责资本市场部门，当时他管理着该公司大约770亿美元的固定收入投资组合，也包括资本市场部所有的杠杆收购方面的投资。他目前担任Sunny Delight Beverages Co.、Esselte Ltd.、Simcom, Inc.的董事；曾经担任Advantage Sales and Marketing, Inc. 和 CHG Healthcare Services, Inc.的董事。
- John W. Childs has served as a member of VeraDermics, Incorporated board of directors since September 2021. Since 1995, Mr. Childs has served as Chairman of J.W. Childs Associates, L.P. Previously, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company and held various executive positions in the investment area at the Prudential Insurance Company of America, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. Mr. Childs is currently a member of the board of directors of Biohaven Ltd., or Biohaven. Mr. Childs received his B.A. in History and French from Yale University and his M.B.A. from Columbia Business School at Columbia University.
高管简历
中英对照 | 中文 | 英文- Michael V. Greco
MichaelV.Greco自2018年6月起担任我们的总法律顾问兼秘书。在加入我们之前，Greco先生于2007年2月至2018年6月在亚力兄制药公司法律部门担任越来越重要的职务，最近于2015年8月至2018年6月担任法律高级副总裁兼公司秘书。任职Alexion公司之前，他曾担任Wiggin and Dana LLP（从2005年5月到2007年2月）、Bingham McCutchen LLP（现称为Morgan，Lewis&Bockius LLP）的公司和交易律师（从1999年9月到2005年5月）。在进入法学院之前，Greco先生曾在美国陆军工程兵部队（U.S.Army Corps of Engineers）服役。他在萨福克大学法学院（Suffolk University Law School）获得法学博士学位，在西点军校（United States Military Academy，West Point）获得工商管理硕士学位。
Michael V. Greco has served as VeraDermics, Incorporated General Counsel since July 2025. From April 2020 until July 2025, he served as General Counsel and Secretary of Rallybio Corporation. From June 2018 until October 2019, he served as General Counsel and Secretary of SpringWorks Therapeutics, Inc. From February 2007 until June 2018, Mr. Greco held positions of increasing responsibility in the legal department at Alexion Pharmaceuticals, Inc., most recently as Senior Vice President of Law and Corporate Secretary from August 2015 to June 2018. Prior to Alexion, he was a corporate and transactional attorney in private practice at Bingham McCutchen LLP (now Morgan, Lewis & Bockius LLP) and Wiggin and Dana LLP. Prior to attending law school, Mr. Greco served in the U.S. Army Corps of Engineers. He received a J.D. from Suffolk University Law School and a B.S. from the United States Military Academy, West Point.- MichaelV.Greco自2018年6月起担任我们的总法律顾问兼秘书。在加入我们之前，Greco先生于2007年2月至2018年6月在亚力兄制药公司法律部门担任越来越重要的职务，最近于2015年8月至2018年6月担任法律高级副总裁兼公司秘书。任职Alexion公司之前，他曾担任Wiggin and Dana LLP（从2005年5月到2007年2月）、Bingham McCutchen LLP（现称为Morgan，Lewis&Bockius LLP）的公司和交易律师（从1999年9月到2005年5月）。在进入法学院之前，Greco先生曾在美国陆军工程兵部队（U.S.Army Corps of Engineers）服役。他在萨福克大学法学院（Suffolk University Law School）获得法学博士学位，在西点军校（United States Military Academy，West Point）获得工商管理硕士学位。
- Michael V. Greco has served as VeraDermics, Incorporated General Counsel since July 2025. From April 2020 until July 2025, he served as General Counsel and Secretary of Rallybio Corporation. From June 2018 until October 2019, he served as General Counsel and Secretary of SpringWorks Therapeutics, Inc. From February 2007 until June 2018, Mr. Greco held positions of increasing responsibility in the legal department at Alexion Pharmaceuticals, Inc., most recently as Senior Vice President of Law and Corporate Secretary from August 2015 to June 2018. Prior to Alexion, he was a corporate and transactional attorney in private practice at Bingham McCutchen LLP (now Morgan, Lewis & Bockius LLP) and Wiggin and Dana LLP. Prior to attending law school, Mr. Greco served in the U.S. Army Corps of Engineers. He received a J.D. from Suffolk University Law School and a B.S. from the United States Military Academy, West Point.
- Reid Waldman
雷德·沃尔德曼是联合创始人，自2022年12月起担任首席执行官。在担任首席执行官之前，Waldman博士曾于2020年3月至2022年12月担任首席运营官。Waldman博士自2019年10月起担任董事会成员。从2019年3月至2021年6月，Waldman博士担任康涅狄格大学健康中心的临床试验住院医师，并于2018年6月至2021年6月担任皮肤科住院医师。在住院之前，Waldman医生完成了在Cedars Sinai医疗中心的实习。Waldman博士是一名获得董事会认证的皮肤科医生，并获得了米西堪萨斯城大学6年B. A./M.D.项目的学士和医学博士学位。
Reid Waldman has served as Chief Executive Officer of Veradermics, Incorporated since 2019. Dr. Waldman is a board certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a researcher authoring more than 100 publications. He earned his B.A. and his M.D. degrees from the University of Missouri Kansas City 6 Year B.A./M.D. Program and completed his dermatology residency with a "Distinction in Clinical Trials" at the University of Connecticut.- 雷德·沃尔德曼是联合创始人，自2022年12月起担任首席执行官。在担任首席执行官之前，Waldman博士曾于2020年3月至2022年12月担任首席运营官。Waldman博士自2019年10月起担任董事会成员。从2019年3月至2021年6月，Waldman博士担任康涅狄格大学健康中心的临床试验住院医师，并于2018年6月至2021年6月担任皮肤科住院医师。在住院之前，Waldman医生完成了在Cedars Sinai医疗中心的实习。Waldman博士是一名获得董事会认证的皮肤科医生，并获得了米西堪萨斯城大学6年B. A./M.D.项目的学士和医学博士学位。
- Reid Waldman has served as Chief Executive Officer of Veradermics, Incorporated since 2019. Dr. Waldman is a board certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a researcher authoring more than 100 publications. He earned his B.A. and his M.D. degrees from the University of Missouri Kansas City 6 Year B.A./M.D. Program and completed his dermatology residency with a "Distinction in Clinical Trials" at the University of Connecticut.
- Dominic Carrano
Dominic Carrano自2025年2月起担任首席财务官。Carrano先生于2023年10月至2025年2月担任财务副总裁。Previoly，Carrano先生于2022年10月至2023年10月在Rallybio Corporation担任副总裁、财务和财务总监，并于2020年9月至2022年10月担任财务总监，负责监督财务和会计业务，包括Rallybio Corporation向上市公司的过渡及其后续发行。在加入Rallybio Corporation之前，Carrano先生在亚力兄制药公司担任的SEC报告和技术会计职能部门的职务越来越重要。Carrano先生的职业生涯始于Deloitte & Touche，LLP。Carrano先生获得了康涅狄格大学会计学学士学位和硕士学位。
Dominic Carrano has served as VeraDermics, Incorporated Chief Financial Officer since February 2025. Mr. Carrano served as VeraDermics, Incorporated Vice President, Finance from October 2023 to February 2025. Previously, Mr. Carrano served as Vice President, Finance and Controller from October 2022 to October 2023 and Controller from September 2020 to October 2022 at Rallybio Corporation where he oversaw financial and accounting operations including Rallybio Corporation's transition to a public company and its follow on offering. Prior to Rallybio Corporation, Mr. Carrano held positions of increasing responsibility at Alexion Pharmaceuticals, Inc within the SEC reporting and technical accounting functions. Mr. Carrano began his career at Deloitte & Touche, LLP. Mr. Carrano received his B.S. and M.S. in Accounting from the University of Connecticut.- Dominic Carrano自2025年2月起担任首席财务官。Carrano先生于2023年10月至2025年2月担任财务副总裁。Previoly，Carrano先生于2022年10月至2023年10月在Rallybio Corporation担任副总裁、财务和财务总监，并于2020年9月至2022年10月担任财务总监，负责监督财务和会计业务，包括Rallybio Corporation向上市公司的过渡及其后续发行。在加入Rallybio Corporation之前，Carrano先生在亚力兄制药公司担任的SEC报告和技术会计职能部门的职务越来越重要。Carrano先生的职业生涯始于Deloitte & Touche，LLP。Carrano先生获得了康涅狄格大学会计学学士学位和硕士学位。
- Dominic Carrano has served as VeraDermics, Incorporated Chief Financial Officer since February 2025. Mr. Carrano served as VeraDermics, Incorporated Vice President, Finance from October 2023 to February 2025. Previously, Mr. Carrano served as Vice President, Finance and Controller from October 2022 to October 2023 and Controller from September 2020 to October 2022 at Rallybio Corporation where he oversaw financial and accounting operations including Rallybio Corporation's transition to a public company and its follow on offering. Prior to Rallybio Corporation, Mr. Carrano held positions of increasing responsibility at Alexion Pharmaceuticals, Inc within the SEC reporting and technical accounting functions. Mr. Carrano began his career at Deloitte & Touche, LLP. Mr. Carrano received his B.S. and M.S. in Accounting from the University of Connecticut.
- Tim Durso
Tim Durso是联合创始人，自2020年8月起担任总裁。杜尔索医生还曾在Edward Hines VA医院担任皮肤科医生。2016年7月至2022年6月，杜尔索博士担任马尔科姆格罗医疗诊所和外科中心皮肤科主任。杜尔索博士完成了他在圣安东尼奥制服服务健康教育联盟的实习和皮肤科住院医师，普雷维奥利在美国空军服役。杜尔索博士是一名获得委员会认证的皮肤科医生，他在圣母大学获得了预医学研究以及希腊和罗马文明的学士学位，并在洛约拉大学芝加哥斯特里奇医学院获得了医学博士学位。
Tim Durso is VeraDermics, Incorporated co founder and has served as VeraDermics, Incorporated Chief Technical Officer since January 2026, and previously as VeraDermics, Incorporated President from August 2020 until January 2026. Dr. Durso has also served as a Dermatologist at Edward Hines VA Hospital. From July 2016 to June 2022, Dr. Durso served as the Chief of Dermatology at the Malcolm Grow Medical Clinics and Surgery Center. Dr. Durso completed his internship and dermatology residency at the San Antonio Uniformed Services Health Education Consortium, and previously served on active duty in the U.S. Air Force. Dr. Durso is a board certified dermatologist and received his B.S. in Pre Medical Studies and Greek and Roman Civilizations from the University of Notre Dame and his M.D. from Loyola University Chicago Stritch School of Medicine.- Tim Durso是联合创始人，自2020年8月起担任总裁。杜尔索医生还曾在Edward Hines VA医院担任皮肤科医生。2016年7月至2022年6月，杜尔索博士担任马尔科姆格罗医疗诊所和外科中心皮肤科主任。杜尔索博士完成了他在圣安东尼奥制服服务健康教育联盟的实习和皮肤科住院医师，普雷维奥利在美国空军服役。杜尔索博士是一名获得委员会认证的皮肤科医生，他在圣母大学获得了预医学研究以及希腊和罗马文明的学士学位，并在洛约拉大学芝加哥斯特里奇医学院获得了医学博士学位。
- Tim Durso is VeraDermics, Incorporated co founder and has served as VeraDermics, Incorporated Chief Technical Officer since January 2026, and previously as VeraDermics, Incorporated President from August 2020 until January 2026. Dr. Durso has also served as a Dermatologist at Edward Hines VA Hospital. From July 2016 to June 2022, Dr. Durso served as the Chief of Dermatology at the Malcolm Grow Medical Clinics and Surgery Center. Dr. Durso completed his internship and dermatology residency at the San Antonio Uniformed Services Health Education Consortium, and previously served on active duty in the U.S. Air Force. Dr. Durso is a board certified dermatologist and received his B.S. in Pre Medical Studies and Greek and Roman Civilizations from the University of Notre Dame and his M.D. from Loyola University Chicago Stritch School of Medicine.
- Mark Neumann
Mark Neumann自2025年12月起担任首席商务和战略官。Previoly，Neumann先生于2018年10月至2025年4月担任Intra Cellular Therapies，Inc.的执行副总裁兼首席商务官。在此之前，他曾于2016年9月至2018年9月在安进公司担任副总裁兼骨骼健康、炎症和肾脏病学的全球治疗领域营销主管，并于2014年6月至2016年8月担任美国心脏病学和骨骼健康Biness部门的营销主管。此前，诺伊曼先生在Bristol Myers Squibb Co工作了超过25年，从1988年6月到2014年5月，在销售、营销和财务方面担任了越来越多的职责。他的职业生涯始于Arthur Andersen & Co.的会计师。Neumann先生在拉斐特学院获得了经济学和BINES行政管理学士学位。
Mark Neumann has served as VeraDermics, Incorporated Chief Commercial and Strategy Officer since December 2025. Previously, Mr. Neumann served as EVP and Chief Commercial Officer at Intra Cellular Therapies, Inc. from October 2018 to April 2025. Before that, he worked at Amgen Inc. as Vice President and Global Therapeutic Area Marketing Head for Bone Health, Inflammation, and Nephrology from September 2016 to September 2018 and Head of Marketing for the U.S. Cardiology & Bone Health Business Unit from June 2014 to August 2016. Prior, Mr. Neumann spent over 25 years at Bristol Myers Squibb Co in various roles of increasing responsibility across sales, marketing, and finance from June 1988 to May 2014. He started his career as an accountant at Arthur Andersen & Co. Mr. Neumann received his B.A. in Economics and Business Administration from Lafayette College.- Mark Neumann自2025年12月起担任首席商务和战略官。Previoly，Neumann先生于2018年10月至2025年4月担任Intra Cellular Therapies，Inc.的执行副总裁兼首席商务官。在此之前，他曾于2016年9月至2018年9月在安进公司担任副总裁兼骨骼健康、炎症和肾脏病学的全球治疗领域营销主管，并于2014年6月至2016年8月担任美国心脏病学和骨骼健康Biness部门的营销主管。此前，诺伊曼先生在Bristol Myers Squibb Co工作了超过25年，从1988年6月到2014年5月，在销售、营销和财务方面担任了越来越多的职责。他的职业生涯始于Arthur Andersen & Co.的会计师。Neumann先生在拉斐特学院获得了经济学和BINES行政管理学士学位。
- Mark Neumann has served as VeraDermics, Incorporated Chief Commercial and Strategy Officer since December 2025. Previously, Mr. Neumann served as EVP and Chief Commercial Officer at Intra Cellular Therapies, Inc. from October 2018 to April 2025. Before that, he worked at Amgen Inc. as Vice President and Global Therapeutic Area Marketing Head for Bone Health, Inflammation, and Nephrology from September 2016 to September 2018 and Head of Marketing for the U.S. Cardiology & Bone Health Business Unit from June 2014 to August 2016. Prior, Mr. Neumann spent over 25 years at Bristol Myers Squibb Co in various roles of increasing responsibility across sales, marketing, and finance from June 1988 to May 2014. He started his career as an accountant at Arthur Andersen & Co. Mr. Neumann received his B.A. in Economics and Business Administration from Lafayette College.